Table 3.

Meta-analysis Results for neutropenia.

Compared genotype	Group	No. of studies	No. of participants	OR (95%CI)	P	Test for heterogeneity
						P	I2
TA6/7 vs. TA6/6	All	32	3948	1.71 (1.41-2.08)	< 0.001	0.104	24.8%
	mCRC	19	2801	1.76 (1.40-2.23)	<0.001	0.434	1.8%
	mNSCLC	2	188	1.35 (0.55-3.34)	0.518	0.920	0.0%
	Asian	21	2547	1.56 (1.07-2.27)	0.020	0.011	46.0%
	Caucasian	10	1342	1.86 (1.34-2.60)	<0.001	0.991	0.0%
	Retrospective	14	1468	1.90 (1.43-2.53)	<0.001	0.201	23.3%
	Prospective	15	1448	1.53 (1.15-2.05)	0.004	0.882	0.0%
TA7/7 vs. TA6/6	All	27	3575	5.34 (3.05-9.33)	<0.001	0.003	48.7%
	mCRC	19	2801	5.07 (2.56-10.02)	<0.001	0.001	59.3%
	Asian	15	2154	4.77 (1.71-13.22)	0.003	0.001	62.6%
	Caucasian	11	1362	5.39 (3.43-8.47)	<0.001	0.342	10.7%
	Retrospective	12	1914	5.61 (3.58-8.82)	<0.001	<0.001	69.3%
	Prospective	14	1531	5.81 (3.57-9.47)	<0.001	0.291	14.8%
TA6/7+7/7 vs. TA6/6	All	49	5232	2.15 (1.71-2.70)	<0.001	0.003	39.5%
	mCRC	26	3473	2.47 (1.86-3.27)	<0.001	0.013	42.1%
	Advanced esophageal cancer	2	133	1.20 (0.48-3.05)	0.697	0.691	0.0%
	Advanced GC	4	193	1.40 (0.64-3.06)	0.402	0.759	0.0%
	mNSCLC	4	351	1.79 (0.97-3.33)	0.064	0.432	0.0%
	Asian	35	3715	2.11 (1.54-2.89)	<0.001	<0.001	53.9%
	Caucasian	13	1458	2.29 (1.69-3.08)	<0.001	0.992	0.0%
	Retrospective	18	2318	2.52 (1.64-3.88)	<0.001	<0.001	59.3%
	Prospective	29	2739	1.90 (1.53-2.35)	<0.001	0.530	0.0%
TA7/7 vs. TA6/6+6/7	All	28	3668	4.12 (2.36-7.20)	<0.001	<0.001	60.7%
	mCRC	20	2894	3.70 (1.88-7.30)	<0.001	<0.001	69.4%
	Asian	15	2154	4.16 (1.44-11.99)	0.008	<0.001	68.9%
	Caucasian	12	1455	3.39 (1.92-5.98)	<0.001	0.057	42.7%
	Retrospective	12	1914	3.59 (1.05-12.28)	0.042	<0.001	76.4%
	Prospective	15	1624	4.10 (2.36-7.12)	<0.001	0.088	35.1%

mCRC, metastatic colorectal cancer; GC, gastric cancer; mNSCLC, metastatic non-small-cell lung cancer.